Product Description
CuraVacsCV-MGis a potentialbreakthroughin MG treatmentsand a potential therapeutic revolution for all autoimmune diseases being the first to possibly bring along-lastingimprovement and a potential cure to patients.
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: CuraVac
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Muscle Weakness|Myasthenia Gravis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Myasterix Efficacy Phase 2/3 Study | P3 |
Active, not recruiting |
Myasthenia Gravis|Muscle Weakness |
2019-08-03 |